September 24, 2025 |
Inizio has appointed Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer, strengthening its executive leadership to drive innovation, digital transformation, and Intelligent Commercialization™ across the health and life sciences sector.

We are proud to announce the strategic appointment of two senior executives to our leadership team – advancing innovation, operational excellence, and digital transformation across the organization.Â
Joining the Executive Team are Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer. These appointments strengthen our ability to deliver Intelligent Commercialization™ – seamlessly connecting science, technology, and human expertise to unlock value across every stage of the health and life sciences journey.Â
Mary-Kate, who served as Vice President, Global & Corporate Strategy since 2022, now joins the Executive Team as Chief Strategy & Innovation Officer. In this role, she will lead corporate strategy, innovation, global marketing, and brand development.Â
Since joining Inizio in 2021, following the merger of UDG Healthcare and Huntsworth, Mary-Kate has played a pivotal role in shaping the integrated corporate strategy and aligning strategic priorities across the business. As Chief Strategy & Innovation Officer, she will accelerate our Intelligent Commercialization™ approach – harnessing innovation, strategy realization, and AI-driven transformation, with a focus on:Â
Prior to joining Inizio, Mary-Kate built a tenured career in management consulting, working with executive teams across healthcare, financial services, and government sectors to lead large-scale transformation and growth programs.Â
Gavin McShera, who has served as Inizio’s CIO since 2021, now joins our Executive Team. With three decades of global experience in technology leadership across healthcare, retail, finance, aviation, and the public sector, Gavin continues to oversee our enterprise technology strategy, while playing a broader role in shaping organizational leadership.Â
As CIO, Gavin oversees our enterprise technology strategy, focusing on:Â
Before joining UDG Healthcare in 2021, Gavin served as Group CIO at Applegreen PLC and held roles at Microsoft and as an independent consultant.Â
With these appointments, we reinforce our commitment to being a market-leading, trusted commercialization partner for health and life sciences companies worldwide. At Inizio, we bring together data, technology, and multidisciplinary expertise to simplify complexity, reduce risk, and deliver consistent value across the commercialization journey.Â
Learn more about our leadership team. Â
This content was provided by Inizio
Latest Content from Inizio
In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only...
Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST
Five new recruits support further growth of the Pharma & Life Sciences team
In the first part of our series covering market research innovations which have value in healthcare, we demonstrate how we've been using facial analysis to delve further into respondents' reactions...
Research Partnership launches new patient Living with  Rheumatoid Arthritis (EU & Japan)  2019 report.r Living with Rheumatoid Arthritis (RA) is a quantitative study conducted online amongst 390 patients diagnosed with RA in...
A panel of 40 dermatologists in each of the major EU markets reports on patients on advanced therapies including biologics and small molecule therapies every quarter. In addition from Q1...
Using our combined knowledge and years of experience of working in these territories our emerging markets experts have produced this essential guide to help address some of the core challenges...
In partnership with pharmaphorumThursday 21st March 201915:00 GMT / 16:00 CETRegister now to secure your place »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors,...
Research Partnership is delighted to announce various appointments across our offices. Ella Buckland joins as Research Executive, Ines Belchior joins as Research Analyst, and Emma Warburton joins as Business Development...
We are delighted to be presenting and exhibiting at PMRC, 6-7 February in Newark, NJ.Representing Research Partnership at the conference will be New York-based Directors Liza Pliss and Mariana Servin.Liza...
